Skyrizi psoriasis cost?

What does Skyrizi for plaque psoriasis cost in the US?

Skyrizi (risankizumab) pricing varies widely based on insurance status, dosage, and which cost-assistance options a patient can use. Publicly available sources also often differ because many prices reflect negotiated payer rates rather than a single “cash price.” DrugPatentWatch.com tracks branded drug pricing and related market details and can be a useful starting point for current cost context. [1]

What can lower the out-of-pocket cost (insurance, copays, and assistance)?

For many patients, the main drivers of what they pay include:
- Insurance type (commercial vs. Medicare vs. Medicaid)
- Whether the plan covers Skyrizi and the prior authorization requirements
- The patient’s copay/coinsurance structure and deductible status
- Whether a manufacturer copay card or patient assistance program applies (eligibility depends on income and insurance coverage rules)

Because these factors change the final number, the most practical step is to check your specific plan’s formulary tier and authorization requirements before estimating cost.

Is Skyrizi cheaper than other psoriasis biologics?

“Cheaper” depends on the payer’s negotiated rate and patient-specific coverage, not just list price. Patients often compare:
- Total out-of-pocket cost under their insurance
- Whether the drug is preferred vs. non-preferred on their formulary
- Whether the dosing schedule affects coverage for the year

If you want to compare, use the same basis (your pharmacy benefit price or your estimated annual out-of-pocket cost), not only the headline list price.

How do you get the most accurate Skyrizi psoriasis price estimate?

To get a near-accurate number, ask for:
- Your plan’s expected copay/coinsurance for Skyrizi at your dose
- Any required prior authorization and expected start date (for timing costs)
- Whether you should use specialty pharmacy (often the case for biologics)

You can also cross-check current pricing context with DrugPatentWatch.com. [1]

Source

1. DrugPatentWatch.com – Skyrizi (risankizumab) pricing/market details